Mark Rutstein, MD Bio
Mark Rutstein, MD
![](/documents/364091/13508155/Mark-Rutstein.jpg/e00c7f77-d029-c0ec-9d22-1bf908915292?t=1680323466780)
As Head of Global Oncology Clinical Development, Mark and his team are responsible for the successful clinical development of the Daiichi Sankyo global oncology portfolio – ensuring oncology development has a strong talent base and a culture that values each individual. In his role, Mark partners closely with cross-functional partners and key stakeholders, internally and externally, to support the advancement of the global oncology pipeline.
Prior to joining Daiichi Sankyo, Mark served in a broad range of pharmaceutical positions including oncology drug development at Amgen, Eli-Lilly, Bayer Healthcare, and Bristol-Myers Squibb. Immediately prior to joining Daiichi Sankyo, served as Vice President, Oncology Development at Bristol Myers Squibb while providing oversight to the R&D of several oncology medicines across multiple clinical indications.
Mark has a passion for developing high performing clinical development teams and inspiring people to be the best version of themselves to make a difference for patients. He is driven with urgency to deliver new medicines to cancer patients with a high unmet clinical need.